Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: Correlations with depression and neuroleptic medication
Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: Correlations with depression and neuroleptic medication
复制标题
DOI：
10.1046/j.1471-4159.1996.66041592.x
复制
发表时间：
1996-04-01
影响因子：
4.7
通讯作者：
Francis, PT
中科院分区：
文献类型：
--
作者：
Chen, CPLH;Alder, JT;Francis, PT
研究人员对 20 名社区获得性阿尔茨海默病病例和 16 名年龄、性别、死后延迟和储存相匹配的对照者的额叶和颞叶皮层的突触前血清素标志物、血清素摄取位点以及血清素和 5-羟基吲哚乙酸浓度进行了研究。阿尔茨海默病患者一生中每隔 4 个月进行一次临床评估，包括行为症状。阿尔茨海默病患者颞叶皮层的血清素摄取部位数量显着减少，但额叶皮层却没有。任一区域的血清素或 5-羟基吲哚乙酸浓度均无显着变化。此外，与没有这些症状的阿尔茨海默病患者相比，一生中有持续抑郁症状的阿尔茨海默病患者的两个皮质区域的血清素摄取位点明显较少。接受长期抗精神病药物治疗的阿尔茨海默病患者，与未接受此类治疗的患者相比，额叶皮层中的血清素浓度和颞叶皮层中的 5-羟基吲哚乙酸浓度显着降低。这些数据表明，先前报告一致的血清素能功能障碍的研究可能是无意选择了行为紊乱的阿尔茨海默病病例或接受长期抗精神病药物的病例。这项研究还为使用血清模拟药物治疗行为障碍阿尔茨海默病患者提供了基础。
Presynaptic serotonergic markers, serotonin uptake sites, and concentrations of serotonin and 5-hydroxyindoleacetic acid were studied in the frontal and temporal cortex of 20 community-acquired cases of Alzheimer's disease and 16 controls matched for age, sex, postmortem delay, and storage, Clinical assessments, including behavioural symptoms, of the Alzheimer patients were made at 4-month intervals during life. There was a significant reduction in the number of serotonin uptake sites in Alzheimer cases in temporal but not frontal cortex. There was no significant alteration in the concentrations of serotonin or 5-hydroxyindoleacetic acid in either region. Alzheimer patients who had persistent depressive symptoms during life had significantly fewer serotonin uptake sites in both cortical areas compared with Alzheimer patients without these symptoms, In addition. Alzheimer patients who were receiving chronic neuroleptic medication had significantly lower concentrations of serotonin in frontal cortex and 5-hydroxyindoleacetic acid in temporal cortex than those patients not receiving such treatment. These data suggest previous studies that reported uniform serotonergic dysfunction may have been subject to unintentional selection of behaviourally disturbed Alzheimer cases or those receiving chronic neuroleptic medication. This study also provides a basis for the treatment of behaviourally disturbed Alzheimer patients with serotonomimetics.